Business

Corcept Ties Cushing’s Syndrome Revenue Outlook to Relacorilant Access

The PDUFA decision date is Dec. 17, 2026. Corcept separately sees at least $2 billion in annual revenue from its current Cushing’s syndrome business by decade’s end.

By Helena WardNov 4, 2026, 5:14 PM UTC

Updated Nov 4, 2026, 5:14 PM UTC1 min read

The U.S. Food and Drug Administration’s White Oak campus stands in Silver Spring, Maryland. (AI-generated image / EconoTimes)

Corcept expects the FDA to decide on relacorilant by Dec. 17, 2026, with the drug’s availability tied to a $3 billion to $5 billion 2030 revenue range for its Cushing’s syndrome business.

The company also projected that its existing Cushing’s syndrome business could bring in at least $2 billion per year by the end of the decade. That figure describes the current business, while the higher range includes relacorilant.

The drug’s PDUFA date is Dec. 17, 2026.

Atabak Mokari, Corcept’s chief financial officer and treasurer, reported $340.5 million in revenue for third-quarter 2026. He reaffirmed the company’s 2026 revenue guidance at $1.1 billion to $1.2 billion.

FDA Corcept Therapeutics Relacorilant Cushing’s syndrome

View all

Health

FDA Approves Voceryq for Adults With Recurrent Respiratory Papillomatosis

The accelerated decision followed fewer surgeries in a 32-person study; Inovio must conduct further trials to confirm clinical benefit.

By Naomi CalderOct 30, 2026, 10:11 PM UTC

Health

FDA Revises Warning Labels for Three More Menopause Patches

The U.S. Department of Health and Human Services says patch production has doubled from a year earlier, though local access problems persist.

By Naomi CalderOct 30, 2026, 6:16 PM UTC

Health

Medline Exits Medline Brand Bed Market as FDA Flags Fire Risk

Medline reported two deaths and 16 serious injuries associated with the product issues as of Oct. 20. The FDA says covered products must be removed from use or sale unless corrected.

By Naomi CalderOct 30, 2026, 5:32 PM UTC